USFDA clears Lupins facility
Lupin announced that United States Food and Drug Administration (USFDA) have successfully completed the inspection at its Aurangabad facility.
The said inspection was carried out by USFDA between February 10 and 14, 2020 and concluded without any observations. Nilesh Gupta, Managing Director of Lupin said that the successful completion of USFDA at Lupin’s facility is very encouraging for the company in improving standards of quality and compliance across the company’s manufacturing operations so as to remain committed to uphold the highest quality standards across all the sites.
Lupin is an innovation-led transnational pharmaceutical company, headquartered in Mumbai in India. The company develops and commercialises a wide range of branded and generic formulations, biotechnology products and APIs in various markets.
On Monday, the stock of the company was trading at Rs 712.05, down by 0.81 per cent or Rs 5.80 per share. The 52-week high is Rs 882.15 and 52-week low is Rs 646.20 on BSE.